The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects
the progression of the immune response including autoimmune diseases. Antigen …

Interactions that occur between several tumour necrosis factor (TNF)–TNF receptors that are
expressed by T cells and various other immune and non-immune cell types are central to T …

Cancer cells can evade immune surveillance in the body. However, immune checkpoint
inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other …

Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor
itself, but the immune system combating the cancerous lesion. Of the many approaches …

To generate chimeric Ag receptors (CARs) for the adoptive immunotherapy of cancer
patients with ErbB2-expressing tumors, a single-chain Ab derived from the humanized mAb …

Regulatory T cells (Tregs) constitute a fascinating subpopulation of CD4+ T cells due to their
ability to limit the immune response against self and non-self antigens. Murine models and …

TNFR2+ regulatory T cells preferentially accumulate in the tumor microenvironment, express
high levels of immunosuppressive molecules and possess strong suppressive activity. Our …

Immunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent
antitumor immune responses in preclinical studies, but their clinical use is limited by …

The costimulatory receptor 4-1BB is expressed on activated immune cells, including
activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of …

The tumor necrosis factor receptor family member 4‐1BB plays a key role in the survival of
activated and memory CD8+ T cells. Depending on the disease model, 4‐1BB can …